In its fourth-quarter earnings conference call, Bausch Health Companies (BHC) has highlighted its Bausch + Lomb/International segment and Salix segment as the key growth drivers for the company in fiscal 2018. In fiscal 2018, Bausch Health Companies reported revenues of $8.38 billion, a YoY decline of 3.94% on a reported basis but 2% YoY growth on an organic basis. According to the fourth-quarter earnings investor presentation, Bausch Health Companies has highlighted seven products that have either been recently launched or will be launched in the near future, called the Significant Seven, to emerge as key revenue drivers for the company in future years.
In fiscal 2018, the Bausch + Lomb/International segment reported revenues of $4.66 billion, a YoY decline of 3% on a reported basis but a 4% YoY rise on an organic basis. The segment accounted for 56% of the company’s total revenues in fiscal 2018.
According to the company’s fourth-quarter earnings conference call, the Bausch + Lomb business in the US market grew YoY by 13%, significantly ahead of the 4%–5% growth in the US contact lens market in 2018. In the Global Vision care category, the company has reported robust uptake for its Bausch + Lomb Ultra and Biotrue ONEday contact lenses. In the Global Consumer category, Lumify has already attained a leading position in the Redness Reliever segment with a market share of 28% despite being commercially launched only in May 2018. The company’s glaucoma drug, Vyzulta, has reported a solid 50% sequential rise in total weekly prescriptions written in the fourth quarter.
In fiscal 2018, the Salix segment reported revenues of $1.75 billion, a YoY rise of 12% on a reported basis as well as an organic basis. The segment accounted for 21% of the company’s total revenues in fiscal 2018. According to the company’s fourth-quarter earnings conference call, this performance was mainly driven by a 22% YoY rise in Xifaxan’s revenues. With almost 90% volumes of the IBS-D market being served by antispasmodics and antidiarrheals, Bausch Health Companies anticipates a significant growth opportunity for Xifaxan in future years.
Finally, according to the fourth-quarter earnings investor presentation, Bausch Health Companies expects its Significant Seven products, which include Relistor, SILIQ, Vyzulta, Lumify, Aqualox, Bryhali, and Duobrii, to result in $300 million in annualized revenues in fiscal 2019. The company also expects these products to result in annualized peak sales of more than $1.0 billion by 2022.
To know about growth drivers of Teva Pharmaceutical (TEVA), please read What Are Teva Pharmaceutical’s Key Growth Drivers in 2019?